Prevalence of neoplasms in patients with acromegaly – the need for a national registry
More details
Hide details
Department of Endocrinology, Medical University, Lublin, Poland
Department of Epidemiology and Clinical Research Methodology, Medical University, Lublin, Poland
Institute of Rural Health, Lublin, Poland
Acromegaly is an endocrine disorder caused predominantly by pituitary adenoma leading to autonomic oversecretion of growth hormone and secondary elevation of insulin-like growth factor 1 (IGF-1). Consequently, there are both theoretical and experimental grounds for establishing a correlation between this disorder and the higher incidence of neoplasms.

The aim of the study is to evaluate the incidence and types of neoplasms among patients with acromegaly.

Material and methods:
The study included 67 patients with acromegaly, aged between 24 and 75±18.8 years, 46 women (68.7%) and 21 men (31.3%), BMI: 30.7±5.7 kg/m2, age at diagnosis 49.1±12.5 years, with the medians of GH and IGF-1 levels at diagnosis of 11.3 ng/ml and 663.8 ng/ml, respectively. A retrospective analysis of medical records with particular regard to physical examination, medical history, laboratory and imaging tests was performed.

Fifty-one patients (76.1%) suffered from at least one neoplasm, among whom 48 patients (71.6%) had benign proliferations, whereas malignant neoplasms (larynx, endometrial and colon cancers) were found in only three patients (4.5%).

Benign neoplasms were found in majority of patients with acromegaly (71.6%) most notably: nodular goiter and colon polyps; malignant lesions were rare (4.5%). Only every fifth patient suffered from no neoplastic proliferations. No correlations between the studied parameters and the incidence of neoplasms were found, most likely due to the small number of patients. This is the reason for proposing the creating of the first national register of incidences of neoplasms among acromegalic patients.

Matyjaszek-Matuszek Beata   
Department of Endocrinology at Medical University, Lublin, Jaczewskiego 8, 20-954 Lublin, Poland
1. Kałużny M, Bolanowski M. Acromegaly-from myths to facts. Endokrynol Pol. 2008 May-Jun; 59(3): 242–4. PMID:18615400.
2. Zgliczyński W. Postępy w rozpoznawaniu i leczeniu akromegalii. Postępy Nauk Medycznych. 2008; 2: 64–8.
3. Holdaway IM, Rajasoorya C. Epidemiology of acromegaly. Pituitary. 1999; 2: 29–41. doi:10.1023/A:1009965803750.
4. Rocznik Demograficzny GUS. Zakład Wydawnictw Statystycznych. Warszawa, 2016, 30 (in Polish).
5. Orme SM, McNally RJQ, Cartwright RA, et al. Mortality and cancer incidence in acromegaly: a retrospective cohort study. J Clin Endocrinol Metab. 1998, 83: 2730–4. doi:10.1210/jcem.83.8.5007.
6. Colao A, Ferone D, Marzullo P, et al. Systemic complications of acromegaly: epidemiology, pathogenesis and management. Endocrine Rev. 2004; 25: 102–152. doi:10.1210/er2002-0022.
7. Renehan AG, Brennan BM. Acromegaly, growth hormone and cancer risk. Best Pract Res Clin Endocrinol Metab. 2008; 22(4): 639–57. doi: 10.1016/j.beem.2008.08.011.
8. Jenkins PJ, Mukherjeet A, Shalett SM. Does growth hormone cause cancer? Clin Endocrinol. 2006; 64: 115–21. PMID: 16430706 doi:10.1111/j.1365-2265.2005.02404.x.
9. Chabra Y, Waters MJ, Brooks AJ. Role of the growth hormone-IGF-1axis in cancer. Expert Rev Endocrinol Metabolism. 2011; 6(1): 71–84. doi:10.1586/eem.10.73.
10. Tornell J, Carlsson B, Pohjanen P, et al. High frequency of mammary adenocarcinomas in metallothionein promoter-human growth hormone transgenic mice created from two different strains of mice. J Steroid Biochem Molec Biol. 1992; 43: 237–42. PMID: 1525063.
11. Bates P, Fisher R, Ward A, et al. Mammary cancer in transgenic mice expressing insulin-like growth factor II (IGF-II). British J Cancer. 1995; 72: 1189–93. PMID: 7577466 PMCID: PMC2033962.
12. Yang XF, Beamer WG, Huynh H, et al. Reduced growth of human breast cancer xenografts in hosts homozygous for the lit mutation. Cancer Res. 1996; 56: 1509–11. PMID:8603394.
13. Wu Y, Cui K, Miyoshi K, et al. Reduced circulating insulin-like growth factor I levels delay the onset of chemically and genetically induced mammary tumors. Cancer Res. 2003; 63: 4384–8. PMID: 12907608.
14. Bałdys-Waligórska A, Krzentowska A, Gołkowski F, et al. The prevalence of benign and malignant neoplasms in acromegalic patients. Endokrynol Pol. 2010; 61(1): 29–34. PMID:20205101.
15. Bolanowski M, Ruchała M, Zgliczyński W, et al. Acromegaly-a novel view of the patient. Polish proposal for diagnostic and therapeutic procedure in the light of recent reports. Endokrynol Pol. 2014; 65(4): 326–31. doi:10.5603/EP.2014.0045.
16. Kurimoto M, Fukuda I, Hizuka N, et al. The prevalence of benign and malignant tumors in patients with acromegaly at a single institute. Endocr J. 2008; 55(1): 67–71. PMID:18202526.
17. Lesen E, Granfeldt D, Houchard A, et al. Comorbidities and treatment patterns among patients with acromegaly in Sweden: a register-linkage population-based study. Endocrine Abstracts. 2016, 41: EP873 doi:10.1530/endoabs.41.EP873.
18. Rokkas T, Pistiolas D, Sechopoulos P, et al. Risk of colorectal neoplasm in patients with acromegaly: a meta-analysis. World J Gastroenterol. 2008; 14: 3484–9. PMID: 18567075 PMCID: PMC2716609.
19. Woliński K, Czarnywojtek A, Ruchała M. Risk of thyroid nodular disease and thyroid cancer in patients with acromegaly: a Meta -analysis and systemic review. PLoS One. 2014 Feb 14; 9(2) doi:10.1371/journal.pone.0088787.
20. Nabarro JDN. Acromegaly. Clin Endocrinol. (Oxf). 1987 Apr; 26(4): 481–512. PMID:3308190.
21. Melmed S. Acromegaly and cancer: not a problem? J Clin Endocrinol Metab. 2001; 86: 2929–34. PMID: 11443145 doi:10.1210/jcem.86.7.7635.
22. Petroff D, Tönjes A, Grussendorf M, et al. The Incidence of Cancer Among Acromegaly Patients: Results from the German Acromegaly Registry. J Clin Endocrinol Metab. 2015 Oct; 100(10): 3894–902. doi:10.1210/jc.2015-2372.
23. Baris D, Gridley G, Ron E, et al. Acromegaly and cancer risk: a cohort study in Sweden and Denmark. Cancer Causes Control. 2002; 13: 395. doi:10.1023/A:1015713732717.